The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and ...

Clearmind Medicine (CMND) has signed a non-binding Letter of Intent with Polyrizon (PLRZ) to develop a novel intranasal formulation for its ...